Takeda Pharmaceutical Company Limited

Scohia Pharma, Inc.

Zenichi Ikeda

Keiko Kakegawa

Minoru Sasaki

Fumiaki Kikuchi

Yoichi Nishikawa

Hideki Hirose

Tsuneo Yasuma

Tohru Yamashita

Takuya Fujimoto

Koji Watanabe

Kazuaki Takami

Masataka Murakami

Ikuo Fujimori

Shuji Kitamura

Yuta Tanaka

Takafumi Yukawa

Ryo Mizojiri

Minoru Ikoma

Sachie Morimoto

Takeshi Yamamoto

Hideyuki Sugiyama

Masahiro Ito

Minoru Nakamura

Masaki Seto

Makoto Kamata

Takuto Kojima

Taiji Asami

Yasuyoshi Arikawa

Tomohiro Okawa

Masaki Daini

Yasutomi Asano

Shigekazu Sasaki

Hironobu Maezaki

Ayumu Sato

Tohru Miyazaki

Satoshi Mikami

Koichiro Fukuda

Naoki Nishizawa

Jinichi Yonemori

Kenjiro Sato

Yasuhiro Imaeda

Yoshihiro Banno

Shinobu Sasaki

Tomoya Yukawa

Masahiro Kamaura

Nobuyuki Matsunaga

Misaki Homma

Asato Kina

Kazuko Yonemori

Akinori Toita

Tomohiro Ohashi

Hironori Kokubo

Takahito Kasahara

Osamu Kubo

Nao Morishita

Kyoko Toyofuku

Takeshi Yasui

Florian Pünner

The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

HDAC6 inhibitory heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. 

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]. 

Condensed heterocyclic compound

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein,or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Bicyclic compound

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

Growing community of inventors

Kanagawa, Japan

Zenichi Ikeda